Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 402

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 402
---
 2023.

The Company currently operates only in the United States and there were no long-lived assets outside of the United States as of December 31, 2024 and 2023.

#### 16. Subsequent Events
The Company evaluated subsequent events through the date these consolidated financial statements were issued to determine if they must be reported. The management of the Company determined there were no reportable subsequent events other than as described below.

#### Clinical Trial Funding Agreement
Subsequent to December 31, 2024, pursuant to the Clinical Trial Funding Agreement, the Company received cash of $552,000 from TuHURA to reimburse the Company for clinical trial expenses related to KVA12123 and received cash of $250,000 as a loan.

#### Pacira Asset Sale
On January 8, 2025, Kineta’ subsidiary, KCP, entered into an exclusivity agreement (“KCP506 Exclusivity Agreement”) with Pacira Pharmaceuticals, Inc. (“Pacira”). Pursuant to the KCP506 Exclusivity Agreement, the Company received cash of $50,000 as an exclusivity payment from Pacira in January 2025.

On February 4, 2025, KCP entered into an Asset Purchase Agreement (the “Pacira APA”) with Pacira. Under the terms of the Pacira APA, Pacira will acquire certain assets from Kineta related to the development of KCP-506. The assets being acquired include intellectual property rights, assumed contracts, permits, inventory, tangible personal property, business records, warranties, and deposits. The purchase price for these assets is $450,000, which will be paid in cash, plus the assumption of certain liabilities associated with the acquired assets. The Pacira APA stipulates that the assets will be transferred free and clear of all encumbrances. Additionally, the Pacira APA includes provisions for indemnification, confidentiality, and further assurances to facilitate the smooth transfer and continued operation of the acquired assets. The closing of the transaction is subject to customary closing conditions and is expected to occur in the first quarter of 2025. In February 2025, the Company received cash of $450,000 pursuant to the asset purchase agreement.

#### HCRX Asset Sale
The license agreements with each of Merck & Co., Inc., Genentech, Inc. and FAIR Therapeutics, B.V., (collectively, the “Partnered Programs”) were sold to HCRX pursuant to the HCRX Agreement, pursuant